BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 25, 2003
 |  BioCentury  |  Strategy

Delivering Cima

In pitching a competitive bid for Cima Labs Inc., Cephalon Inc. is hoping that it can build a franchise out of its fentanyl business and leverage its drug delivery technologies, which are currently gathering dust.
CEPH (West Chester, Penn.) last week proposed to acquire CIMA (Eden Prairie, Minn.) for $26 per share in cash, valuing the company at $376.6 million. The bid competes with a stock offer from aaiPharma Inc., which values CIMA at $368 million based on the closing prices of AAII and CIMA on Aug. 4.
"We like their technology and their business model. They are a profitable drug delivery...

Read the full 495 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >